Texas Hemp Lawsuits Consolidate, DEA Rescheduling Frozen, and the November Cliff

The Weedcoin Team

Individual lawsuits are merging into something bigger. The DEA has no judge. And November is closer than anyone wants to admit.

The Texas hemp industry is not going quietly. What started as individual lawsuits from retailers scrambling to survive is consolidating into a coordinated legal assault on the state's new regulations. Boomtown Vapor LLC, which filed the first major challenge in Travis County on March 17, withdrew its standalone suit last week to join a larger industry coalition preparing a more comprehensive case against the Texas Department of State Health Services.

Meanwhile, the federal rescheduling process that was supposed to be accelerating under President Trump's executive order has hit a wall that nobody is talking about enough: the DEA's administrative law judge retired in July 2025, the hearing was already frozen by an interlocutory appeal, and there is no timeline for resolution. The rescheduling everyone is waiting for may not come until late 2026 or early 2027 -- if it survives the legal challenges that are guaranteed to follow.

And in the background, the November 12 federal hemp cliff approaches. Eleven days until New Jersey. Eighteen days until 4/20. The chess pieces are all moving at once.

The Texas Legal Consolidation

Boomtown Vapor's original lawsuit challenged two core elements of the DSHS rules: the shift from a Delta-9 THC standard to a total THC standard (which captures THCA and effectively bans hemp flower), and the $5,000 annual retail registration fee that the company called a "prohibitive tax" designed to destroy the industry rather than regulate it.

The lawsuit laid out a clear timeline of how Texas arrived here: the legislature passed HB 1325 in 2019 defining legal hemp based solely on Delta-9 levels, Governor Abbott vetoed Senate Bill 3 in June 2025 (which would have banned most intoxicating hemp products outright), and then Abbott issued Executive Order GA-56 in September 2025 directing DSHS to regulate the market his veto had just saved.

The result, the industry argues, is the ban he vetoed -- delivered through regulatory channels instead of legislative ones.

What is new is that Boomtown Vapor withdrew its petition to join a larger coalition suit. Comments on the original filing confirmed it: "This lawsuit was withdrawn as they are joining a larger group to file a bigger suit." Multiple smoke shop owners echoed the sentiment -- "most shops are going to sue."

The consolidation matters because a coordinated challenge from an industry coalition carries more legal weight, more resources, and more political pressure than scattered individual lawsuits. The Texas Hemp Business Council has signaled its involvement. The legal argument -- that DSHS exceeded its statutory authority by redefining hemp beyond what the legislature authorized -- has a real foundation given Abbott's own veto of a legislative approach to the same restrictions.

Meanwhile, the Texas Supreme Court is still expected to hear the 2021 Delta-8 classification case this year. The combination of the coalition lawsuit and the Supreme Court case could reshape Texas hemp law significantly -- but not quickly enough to save the businesses that have already closed.

DEA Rescheduling: Frozen in Place

Here is the state of federal rescheduling as of April 2, 2026.

President Trump's December 18, 2025 executive order directed the attorney general to move marijuana from Schedule I to Schedule III "in the most expeditious manner." That sounds decisive. The reality is anything but.

The DEA published its proposed rulemaking in May 2024. Over 42,000 public comments were submitted, a majority supporting the move. The DEA then announced an administrative hearing -- standard procedure for formal rulemaking under the Controlled Substances Act.

That hearing was scheduled for January 21, 2025. It never happened. An administrative law judge postponed it on January 13 while an interlocutory appeal about alleged bias and improper communications among DEA leadership is resolved. The proceedings are stayed. No briefing schedule has been set for the appeal.

Then, in July 2025, the presiding Chief Administrative Law Judge who was overseeing the entire record retired -- leaving the DEA without a judge for future hearings.

So the situation is: the hearing is frozen, the judge is gone, the appeal has no timeline, and the executive order has no mechanism to bypass the administrative process that is stuck. Legal experts at the National Law Review project the realistic timeline for a final rescheduling rule is late 2026 to early 2027 -- and that assumes no additional legal challenges, which are guaranteed.

For the cannabis industry, this means the single most anticipated federal policy change remains in limbo. The 280E tax burden that crushes cannabis operators continues. Research barriers persist. Federal-state tensions remain unresolved.

The executive order changed the conversation. It has not yet changed the law.

Multiple sclerosis patient using a wheelchair in a sunlit room with cannabis oil nearby

The November Cliff

While everyone watches Texas and the DEA, the federal hemp deadline on November 12, 2026 approaches with less fanfare and potentially more devastation.

The legislation signed by President Trump in November 2025 fundamentally redefines legal hemp. The changes: a shift to total THC (capturing THCA and all isomers), a per-container cap of 0.4 milligrams of total THC (not per serving -- per container), and a ban on intermediate hemp-derived cannabinoid products marketed directly to consumers.

A JD Supra analysis from the National Law Review breaks down what this means practically: delta-8 gummies, THCA flower, THC-O products, high-potency edibles, and many "full-spectrum" SKUs cannot survive the new per-container ceiling without significant reformulation, repackaging, or discontinuation. The hemp industry built a roughly $30 billion market in the gap between the 2018 Farm Bill and regulatory catch-up. That gap closes November 12.

New Jersey's April 13 deadline -- now 11 days away -- is the next domino before the federal cliff. Governor Murphy's January legislation follows the same total-THC playbook. Only licensed cannabis dispensaries can sell THC products after that date.

A bill was introduced on January 12, 2026 to delay the federal restrictions by two years. Legal analysts caution that businesses should treat a delay as upside, not as the operating assumption.

Cannabis and Multiple Sclerosis: What the Evidence Shows

Today's cannabis benefits section covers multiple sclerosis and spasticity -- an area where the clinical evidence is strong enough that one cannabis-based medication is already approved in over 30 countries.

Nabiximols (marketed as Sativex) is a standardized whole-plant cannabis extract containing roughly equal parts THC and CBD, delivered as an oral spray. It is approved in more than 30 countries for MS-related spasticity, though it remains unavailable in the United States.

A comprehensive meta-analysis published in Clinical Therapeutics found that cannabis-based therapies are associated with clinically meaningful improvements in MS-related spasticity, particularly over longer treatment durations. Short-term studies showed modest improvements, while long-term studies demonstrated substantially greater benefits -- suggesting that cannabinoid therapy for spasticity may require sustained use to achieve full effectiveness.

The Multiple Sclerosis Extract of Cannabis trial demonstrated a twofold increased rate of relief from muscle stiffness with oral cannabis extract containing THC after 12 weeks. Patient-reported outcomes showed improvements in spasticity relief, physical and psychological impact, and walking ability.

A Cochrane review -- considered the gold standard for evidence-based medicine -- concluded that nabiximols have moderate certainty evidence for spasticity improvement, with the greatest effectiveness seen in patients with moderate to severe spasticity who have not responded well to other treatments. Adverse effects were predominantly mild: dizziness, dry mouth, and fatigue.

The mechanism involves the endocannabinoid system's role in regulating muscle tone and neural signaling. THC and CBD interact with CB1 and CB2 receptors throughout the central nervous system, modulating the overactive nerve signals that cause the involuntary muscle tightness and spasms characteristic of MS.

For the roughly one million Americans living with MS, spasticity is one of the most debilitating symptoms -- affecting mobility, sleep, and quality of life. The fact that a cannabis-based treatment is approved in 30 countries but not the United States is one of the clearest examples of how federal scheduling has held back patient access.

Solana: Holding the Line at $80

Solana enters April under technical pressure. SOL trades around $83 after six consecutive monthly declines, with a bearish head-and-shoulders pattern on daily charts projecting a potential move to $73. The 20-day EMA at $86 is the key resistance level -- reclaiming it would signal short-term recovery toward $93.

Cumulative US spot SOL ETF inflows sit at $979 million, though the last several days saw modest outflows. Exchange buying pressure dropped 80 percent in the final week of March.

The $80 support level is critical. A daily close below it reinforces the bearish case. Above $86, the picture changes significantly.

For Weedcoin, the fundamental thesis remains: Solana's infrastructure continues to strengthen regardless of price action. The Alpenglow consensus upgrade targeting 150-millisecond finality, the Firedancer validator client, and institutional stablecoin adoption (Visa, Western Union) all continue to build the network underneath us.

Eighteen days to 4/20. The lawsuits are consolidating. The process is frozen. The cliff is approaching. And we are still here.